Syndromic Infectious Disease Diagnostics Market is expected to reach USD 3.9 billion by 2031

Syndromic Infectious Disease Diagnostics Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the syndromic infectious disease diagnostics market will expand from USD 3.1 billion in 2026 to USD 3.9 billion in 2031 at a CAGR of 4.7% during the forecast period.

Syndromic infectious disease diagnostics refers to the use of multiplex molecular diagnostics to identify multiple pathogens associated with a clinical syndrome using a single test platform. The majority of syndromic infectious disease diagnostics systems are usually on a single test platform to test patients who have signs/symptoms consistent with respiratory illness, bloodstream infections, gastrointestinal illnesses, meningitis, and to test patients with emerging viral diseases. According to the CDC's March 2026 report, the sensitivity associated with the use of nucleic acid detection assays for rapid molecular influenza testing using various FDA-cleared testing platforms is between 90-95%; results from these tests can be produced in 15-30 minutes (based on FDA-cleared testing platform). The increased utilisation of multiplex RT-PCR systems will support infection control efforts, promote responsible use of antimicrobials by preventing unnecessary prescriptions of antibiotics for viral infections, improve preparedness for disease outbreaks, and improve efficiency in campus/clinical workflow. Agencies at the federal level are encouraging the use of multiplex testing to differentiate respiratory viruses from other infectious diseases and to manage patients with newly emerging infectious diseases..

Request a free sample copy or view the report summary: Syndromic Infectious Disease Diagnostics Market Report

Syndromic Infectious Disease Diagnostics Market Report Highlights

• CDC’s Flu SC2 Multiplex Assay simultaneously detects influenza A, influenza B, and SARS-CoV-2 infections using one RT-PCR diagnostic test.

• CDC reported rapid molecular influenza assays demonstrate approximately 90–95% sensitivity with results generated within 15–30 minutes.

• CDC expanded its Infectious Diseases Laboratory Test Directory in April 2026 to strengthen infectious disease molecular testing accessibility.

• Multiplex PCR technologies are increasingly being deployed for emerging pathogen differentiation, including 2026 monkeypox clade identification workflows.

Syndromic Infectious Disease Diagnostics Market Growth Drivers and Restraints

Growth Drivers:

• Due to the heightened need for respiratory infectious disease monitoring, there is a surge in demand for multiplexing syndromic diagnostic tests. In September 2025, the CDC communicated that multiplex molecular assays that can concurrently identify influenza A, influenza B, and SARS-CoV-2 strains could be performed with just one diagnostic workflow. The agency explained that multiplex testing enhances laboratory efficiencies, optimizes the use of testing materials, and illustrates support for public health surveillance initiatives. Moreover, the CDC's March 2026 influenza molecular testing advisory communicated that the sensitivity of rapid FDA-cleared nucleic acid amplification test systems is approximately 90% - 95%, and that results can be performed in less than 30 minutes for specific systems. Accelerating trends for co-circulating respiratory viruses; hospital infection control requirements; and demand for a quicker means of making therapeutic decision are rapidly increasing the acceptance of multiplex PCR-based syndromic testing platforms throughout the world.

• Expansion of government-backed molecular diagnostics testing infrastructure is driving market growth. The CDC published an updated Infectious Diseases Laboratory Test Directory in April 2026, increasing the number of available molecular testing resources in the infectious disease categories. CDC's published updated dengue testing guidance also supports azymotic acids amplification techniques to increase early detection of viral infection through publication of its updated dengue testing guidance also supports azymotic acid amplification testing for early detection of viral disease. CDC-supported research demonstrates the capability of multiplex PCR workflow designs to differentiate monkeypox clades for outbreak surveillance application in February 2026. These advancements provide an increased amount of institutional investment into multiplex molecular diagnostics for rapid identification of pathogens, outbreak preparation and accurate management of infectious diseases. Additionally, expansion of automated molecular laboratory systems and decentralized testing capabilities continues to strengthen their penetration in hospitals and public health networks.

Restraints:

• High device costs, cybersecurity concerns, and regulatory compliance challenges continue limiting wearable diagnostic biosensor adoption. Government healthcare agencies in 2025 highlighted increasing concerns regarding patient data privacy, interoperability standards, and clinical validation requirements. Limited reimbursement coverage and technical inaccuracies in continuous monitoring systems also restrict wider adoption across developing healthcare markets.

Syndromic Infectious Disease Diagnostics Market Growth Key Development

• June 2025: bioM?©rieux strengthened its antimicrobial resistance diagnostics capabilities by acquiring assets from Day Zero Diagnostics, a company specialising in genome sequencing and machine learning-based infectious disease detection. This acquisition enables faster identification of pathogens and their antibiotic resistance profiles directly from blood samples, significantly reducing diagnostic time from days to hours.

• January 2026 – Thermo Fisher Scientific expanded automated molecular diagnostic systems supporting high-throughput syndromic testing for respiratory and bloodstream infections, improving turnaround time and hospital laboratory workflow efficiency.

• February 2026 – Roche Diagnostics advanced cobas multiplex respiratory syndromic testing portfolio, enhancing simultaneous detection of multiple viral pathogens in hospital-based molecular diagnostic workflows.

Syndromic Infectious Disease Diagnostics Market Growth Segmentation

Knowledge Sourcing Intelligence has segmented the Syndromic Infectious Disease Diagnostics Market Growth based on product type, technology, application, and region:

Syndromic Infectious Disease Diagnostics Market Growth, By Product Type

• Instruments

• Kits & Reagents

• Software & Services

Syndromic Infectious Disease Diagnostics Market Growth, By Technology

• Polymerase Chain Reaction (PCR)

• Next-Generation Sequencing (NGS)

• Microarray

• Immunoassays

Syndromic Infectious Disease Diagnostics Market Growth, By Application

• Clinical Diagnostics

• Epidemiological Surveillance

Syndromic Infectious Disease Diagnostics Market Growth By Region

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Syndromic Infectious Disease Diagnostics Market Growth Key Players

• Thermo Fisher Scientific

• Roche Diagnostics

• Bio-Rad Laboratories

• QIAGEN

• Danaher Corporation

• Abbott Laboratories

• bioMérieux

• Bruker Corporation

• Accelerate Diagnostics

• Hologic